Vertex Pharma stock gains 3.19% since report as FDA date nears
Published on 10/29/2026 at 17:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline progress and regulatory focus
- Vertex reported positive Phase 3 RAINIER data for povetacicept in IgA nephropathy.
- The FDA has set a November 30 target action date for potential accelerated approval.
- The trial's final analysis will provide longer-term evidence on kidney-function outcomes.
Vertex Pharma stock was at EUR 484.43 at Lang & Schwarz on October 29, 2026, at 5:11 p.m. Berlin time. That was 3.19 percent above the EUR 469.45 level cited in the latest relevant own report from October 26. Separately, the quote stood 2.52 percent above the last completed Xetra close of EUR 472.50 from October 28.
The market update adds a new price reference to the recent kidney-program assessment. It does not by itself establish a causal link between the share-price move and Vertex's clinical news.
RAINIER data strengthen the renal case
On October 23, Vertex announced publication in the New England Journal of Medicine and presentation at the American Society of Nephrology Kidney Week of Phase 3 RAINIER results for povetacicept in IgA nephropathy. According to the Vertex Pharmaceuticals release, the study met its primary endpoint and both secondary endpoints.
At Week 36, proteinuria fell 52.0 percent from baseline with povetacicept, corresponding to a 49.8 percent reduction versus placebo. The company also reported that 42.2 percent of treated participants reached a 24-hour urine protein-to-creatinine ratio below 0.5 grams per gram, compared with 6.2 percent on placebo.
Approval remains the next catalyst
Vertex said the data support its biologics license application for accelerated approval in adults with IgA nephropathy. The U.S. Food and Drug Administration's PDUFA target action date is November 30, 2026. The RAINIER trial continues in a blinded manner toward its longer-term Week 104 analysis, so the interim findings do not yet settle the effect on subsequent kidney-function decline.
For investors, povetacicept provides a potential renal pillar alongside Vertex's established cystic-fibrosis business and newer products. The regulatory decision and the November 2 earnings release are separate events and should be assessed independently.
The real-time quote of Vertex Pharma stock provides the latest market indication.
Vertex Pharmaceuticals market data
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- Ticker: VRTX
- Home exchange: Nasdaq
- Lang & Schwarz quote: EUR 484.43 on October 29, 2026, at 5:11 p.m. Berlin time
- Change from latest own report: Up 3.19 percent from EUR 469.45 on October 26, 2026
- Last completed Xetra close: EUR 472.50 on October 28, 2026
- 52-week range: USD 403.16 to USD 560.25 as of October 29, 2026
The broader market environment can be followed through the S&P 500 market topic.
